SELEXYS PHARMACEUTICALS CORPORATION

Company Information

Company Name
SELEXYS PHARMACEUTICALS CORPORATION
Address
840 RESEARCH PKWY, STE 516
OKLAHOMA CITY, OK, -
Phone
n/a
URL
n/a
DUNS
145737131
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$6,761,599.00
3
SBIR Phase II
$5,666,256.00
2
Chart code to be here

Award List

  1. Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease

    Amount: $3,113,969.00

    DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowe ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. PEGylation of a Glycosulfopeptide Anti-Inflammatory

    Amount: $304,843.00

    DESCRIPTION (provided by applicant): Normal recruitment of circulating white blood cells (leukocytes) into tissues is important in inflammation, lymphocyte homing, and immunological responses. The me ...

    SBIR Phase I 2004 Department of Health and Human Services
  3. Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

    Amount: $3,342,787.00

    DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with s ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease

    Amount: $2,553,342.00

    DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

    Amount: $3,112,914.00

    DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in pa ...

    SBIR Phase II 2012 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government